Briefly, all patients were pre-treated with trastuzumab in the (neo)adjuvant or metastatic setting and most had received at least 1 line of HER2-targeted treatment for metastatic disease (median 1, range 0–4). Here, ERBB2 is linked to metastatic neoplasm.